< PreviousSCIENTIFIC PROGRAMME80 Saturday, 23 April 2022 O0235Reduced chlorhexidine susceptibility in invasive Klebsiella pneumoniae ST258 bla KPC2- producing isolates M. Roch* (Geneva, Switzerland), R. Sierra, A.C. Gales, D.O. Andrey O0236Emerging threat of carbapenem-resistant and hypervirulent Klebsiella pneumoniae in healthcare setting, South Korea: a retrospective observational, single-centre study M.J. Kim* (Seoul, Korea, Republic of), Y.S. Chung, Y. Jeong O0237Molecular surveillance of NDM-5-producing Escherichia coli revealed the countrywide dissemination of certain high-risk clones in Germany, 2013 to 2019 J.B. Hans* (Bochum, Germany), N. Pfennigwerth, B. Neumann, Y. Pfeifer, M.A. Fischer, J. Eisfeld, J. Schauer, S. Gatermann, G. Werner O0238Molecular features and transmission of NDM- producing Enterobacterales in Israeli hospitals A. Adler* (Tel Aviv, Israel), H. Ghosh, A. Gross, A. Rechavi, M. Lasnoy, M. Assous, Y. Geffen, M. Paul, Y. Wiener-Well, S. Reuter, H. Grundmann O0239High prevalence of OXA-23 carbapenemase- producing Proteus mirabilis among amoxicillin- clavulanate-resistant isolates in France L. Dortet* (Le Kremlin-Bicêtre, France), A. Lombes, R.A. Bonnin, F. Laurent, H. Guet-Revillet, E. Bille, V. Cattoir, M.S. Fangous, C. Le Brun, V. Fihman, F. Janvier, A. Potron, S. Corvec, A. Mizrahi OS05816:15 - 18:15Hall H 2-Hour Oral Session Current treatment approach to COVID-19 ChairsDominique Braun (Zurich, Switzerland) Karine Lacombe (Paris, France) O0240Safety and feasibility of monoclonal antibody therapies in children with SARS-CoV-2 infection L. Romani* (Rome, Italy), S. Bernardi, S. Chiurchiu’, L. Cursi, F.I. Calò Carducci, M. Di Giuseppe, M. De Luca, L. Vallesi, A. Smarrazzo, P. Merli, A. Campana, L. Lancella, E. Nicastri, P. Palma, M. Raponi, P. Rossi O0241Antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital- acquired COVID-19: a single-centre experience A. Faraone* (Florence, Italy), T. Picchioni, G. Scocchera, P. Carrai, A. Lo Forte, S. Sbaragli, M. Bettucchi, A. Fortini O0242Impact of using steroids and interleukin (IL-1 and IL-6) inhibitors on secondary infections and fatality in severe and critical COVID-19 cases Ö. Ergönül* (Istanbul, Turkey), E. Er Gülbezer, M. Kapmaz, P. Irkören, M.G. Gönenli, S. Iliaz, B. Dikenelli, E. Sentürk, S. Tekin, N. Alpay Kanitez O0243Dual monoclonal antibodies in SARS-CoV-2 infected patients: clinical and virological efficacy N. Peiffer-Smadja* (Paris, France), L. Kramer, V.M. Ferré, R. Coppée, A. Kanté, M. Debarge, C. Choquet, T. De Saint Joannis, D. Bouzid, J. Messika, J. Le Grand, M. Thy, S. Kerneis, D. Descamps, J. Ghosn, B. Visseaux O0244Synergistic inhibitory effect of remdesivir and ribavirin against human coronavirus 229E C. García-Crespo* (Madrid, Spain), A.I. De Ávila, I. Gallego, M.E. Soria, B. Martínez-González, L. Vázquez-Sirvent, E. Domingo, C. Perales O0245Use of high-dose casirivimab/imdevimab to treat anti-spike seronegative patients hospitalised with COVID-19: first experiences from a tertiary care centre in Florence, Italy T. Manciulli* (Florence, Italy), M. Spinicci, A. Barbiero, R. Paggi, A. Miftode, M. Tilli, S.T. Kiros, J. Mencarini, F. Lagi, N. Di Lauria, L. Zammarchi, A. Bartoloni O0246Impact of home treatment with glucocorticoids in patients with COVID-19 pneumonia E. Franceschini* (Modena, Italy), A. Dessilani, A. Cozzi-Lepri, V. Iadisernia, M. Digaetano, G. Cuomo, E. Bacca, F. Carli, M. Menozzi, G. Guaraldi, C. Mussini O0247Real-world baricitinib use in critically ill patients with COVID-19 during tocilizumab shortage at a large academic health-system in Miami, Florida K.J. Deronde* (Miami, United States), A.D. Vega, C.A. Vu, R. Boatwright, J.C. Simon, V. Salazar, C.M. Mauriello, E. Cano, R. Rosa, L.M. Abbo O0248Tocilizumab treatment in adult patients with moderate to critical COVID-19 pneumonia: a retrospective study in a teaching hospital of infectious diseases, Cluj-Napoca, Romania M. Muntean* (Cluj-Napoca, Romania), A. Radulescu, A. Istrate, A. Csiszer, R. Dobrota O0249Clinical effectiveness of REGN-COV2, a neutralising antibody cocktail in patients with COVID-19 in Japan: a retrospective cohort study with a bayesian inference N. Amano* (Kakogawa, Japan), S. IwataFINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 202381 Saturday, 23 April 2022 ESCMID presents: EUCAST at ECCMID 2022 Saturday, 23 April 2022 08:30 - 11:30Hall A Educational Workshop EUCAST Educational Workshop Chairs Alasdair P. Macgowan (Bristol, United Kingdom) Arjana Tambi ć -Andraševi ć (Zagreb, Croatia) 08:30EUCAST Update Christian Giske (Stockholm, Sweden) 09:00Putting certainty into antimicrobial susceptibility testing Gunnar Kahlmeter (Växjö, Sweden) 09:30PK/PD breakpoints in the EUCAST breakpoint tables Shampa Das (Liverpool, United Kingdom) 10:00Revising aminopenicillin breakpoints John D. Turnidge (Hawthorn, Australia) 10:30Screening and testing for antifungal resistance Maiken Arendrup (Copenhagen, Denmark) Co-organised with: EUCAST Steering Committee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS) Sunday, 24 April 2022 07:15 - 08:15Hall I Meet-the-Expert EUCAST Frequently Asked Questions 07:15Erika Matuschek (Växjö, Sweden) 07:45Mandy Wootton (Cardiff, United Kingdom) Co-organised with: EUCAST Steering Committee Sunday, 24 April 2022 11:00 - 12:00Hall N Symposium Updates on antimicrobial susceptibility testing of mycobacteria ChairsThomas Schön (Kalmar, Sweden) Florian Maurer (Borstel, Germany) 11:00Updates and open questions on the recently revised WHO critical concentrations for antimicrobial susceptibility testing of Mycobacterium tuberculosis complex Claudio Köser (Cambridge, United Kingdom) 11:30The EUCAST approach for drug susceptibility testing of mycobacteria: past, present, future Emmanuelle Cambau (Paris, France) Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), EUCAST Subcommittee on Antimycobacterial Susceptibility Testing (EUCAST-AMST)SCIENTIFIC PROGRAMME82 Scientific Programme Sunday, 24 April 2022 CM ME05907:15 - 08:15 Hall C Meet-the-Expert External quality assessment in genomics M025007:15Aitana Lebrand (Geneva, Switzerland) M025107:45Denise O’Sullivan (London, United Kingdom) Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), ESCMID Study Group for Epidemiological Markers (ESGEM) IC ME060 07:15 - 08:15 Hall F Meet-the-Expert Nosocomial transmission of SARS-CoV-2: have you looked at all the risks? M025207:15Emine Alp Mese (Ankara, Turkey) M025307:45Michihiko Goto (Iowa City, United States) PH ME061 07:15 - 08:15 Hall G Meet-the-Expert Getting to yes: strengthening vaccine uptake in hard-to- reach and vaccine hesitant communities M025407:15Sally Hargreaves (London, United Kingdom) M025507:45Stephanie Vandentorren (Paris, France) Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM) ID ME062 07:15 - 08:15 Hall H Meet-the-Expert Diagnosis and treatment of herpes simplex encephalitis M025607:15Oguz Resat Sipahi (Izmir, Turkey) M025707:45Jean Paul Stahl (Corenc, France) Co-organised with: Infectious Diseases and Clinical Microbiology Specialty Society of Turkey (EKMUD) CM ME063 07:15 - 08:15 Hall I Meet-the-Expert EUCAST Frequently Asked Questions M025807:15Erika Matuschek (Växjö, Sweden) M025907:45Mandy Wootton (Cardiff, United Kingdom) Co-organised with: EUCAST Steering Committee ID ME06407:15 - 08:15 Hall L Meet-the-Expert Current approaches to prevent invasive fungal diseases in paediatric patients M026007:15Andreas H. Groll (Münster, Germany) M0260A07:45Maria Elena Santolaya (Santiago, Chile) IC ME065 07:15 - 08:15 Hall N Meet-the-Expert Contact precautions and cleaning for MDR prevention M026107:15Stephanie J. Dancer (Glasgow, United Kingdom) M026207:45Gonzalo Bearman (Richmond, United States) Co-organised with: EUCIC Steering Committee ID ME066 07:15 - 08:15 Hall P Meet-the-Expert FDG-PET/CT and outcome of infections in immunosuppressed patients M026307:15Nesrin Ghanem-Zoubi (Haifa, Israel) M026407:45Alfred O. Ankrah (Accra, Ghana) Co-organised with: ESCMID Study Group for Immunocompromised Hosts (ESGICH), International Immunocompromised Host Society (ICHS) Presentations in light grey were not registered at the time of publishing.FINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 202383 KN06708:30 - 10:30 Keynote lecture Excellence Award lectures Chairs Jesús Rodríguez-Baño (Seville, Spain) Maurizio Sanguinetti (Rome, Italy) KN026508:30 Characterising SARS-CoV-2, the virus that caused the COVID-19 pandemic: an ongoing effort Bart Haagmans (Rotterdam, Netherlands) Bart Haagmans is a virologist working at the Viroscience department, Erasmus medical center in Rotterdam, Netherlands. His research line focusses on the pathogenesis of viral infections and especially those viruses that emerge through zoonotic transmission, as a basis for (future) interventions and medical countermeasures. This brings together work performed earlier at the Veterinary faculty in Utrecht and more recent work on human viruses in Rotterdam. He brings a strong track record of fundamental and applied research of MERS-CoV, SARS-CoV and SARS-CoV-2. In collaboration with internationalteams,thenovelcoronaviruswasclassifiedas SARS-CoV-2, diagnostic assays were developed and validated while animal and in vitro organoid models were set up to further understand pathogenesis and test (antibody based) intervention strategies. Development of reagents, vaccines and protocols for molecular and serological detection of these emerging viral pathogens lead to options for interventions and medical countermeasures. Dr. Haagmans has more than 230 publications on different subjects in (clinical) virology, identificationandcharacterizationofnovelemergingviruses and the development of vaccines. He is an expert consultant of WHO, FAO and OIE on coronaviruses as well as a member of the the Coronaviridae Study Group of the ICTV. He is PI on several Dutch and EU grants and is co-coordinating the IMI ZAPI project, focused on zoonotic anticipation and preparedness initiatives, and amongst others led to discovery of broadly cross- reactive monoclonal antibodies against beta coronaviruses. Fireplace Session24 April, 11:00 - 12:00 Hall A Excellence Award lectures Chairs Jesús Rodríguez-Baño (Seville, Spain) Maurizio Sanguinetti (Rome, Italy) K026609:30Transcending European clinical research in infectious diseases through collaboration to break down traditional silos Herman Goossens (Edegem, Belgium) Prof. Herman Goossens is a full professor of Medical Microbiology at the University of Antwerp in Belgium since 1992, director of the laboratory of Clinical Microbiology at the University Hospital Antwerp since 1992 and director of Laboratory Medicine of the University Hospital Antwerp since 1997. His professional goal is to bridge the gap between basic and clinical research, with a major focus on antibiotic resistance, to enhance the standard of healthcare, public health and professional standards, for the good of the public in large. Prof.Goossens’scurrentresearchisfocusedonfiveareas. First, the detection and genetic mechanisms involved in the emergence and evolution of antibiotic resistance and virulence in bacteria and its epidemiological and ecological bases and implications. Second, studying antimicrobial use in hospitals, the community and long-term care facilities, developing indicatorsofuseandqualityofprescribing,initiallyinEurope, later globally, focusing on Low and Middle Income Countries. Third,linkingscientificandclinicalresearchthroughoutEurope in lower respiratory tract infections, in primary health care and hospital medical practice. Fourth, better preparing Europe for emerging infectious diseases and pandemics. Fifth, building a network of more than 800 diagnostic labs in more than 40 countries in Europe to support clinical trials that investigate the utility of new antimicrobial strategies and diagnostics. Prof. Goossens authored more than 600 Web of Science cited papers, and his papers have been cited close to 25,000 times. In 2008 Prof. Goossens obtained the prestigious status of Methusalem top-scientist from the Flemish government. Fireplace Session24 April, 11:00 - 12:00 Sunday, 24 April 2022SCIENTIFIC PROGRAMME84 Sunday, 24 April 2022 CM SY068 08:30 - 10:30 Hall B Symposium New developments in antimicrobial resistance and virulence of anaerobic pathogens ChairsAlida C.M. Veloo (Groningen, Netherlands) Edit Urbán (Pécs, Hungary) S026708:30EUCAST recommended method for antimicrobial susceptibility testing of anaerobic bacteria Erika Matuschek (Växjö, Sweden) S026809:00Carbapenem and metronidazole resistance mechanisms of Bacteroides Jozsef Soki (Szeged, Hungary) S026909:30Bacteroides fragilis: a tale of two habitats Sheila Patrick (Belfast, United Kingdom) S027010:00One step further: complementing phenotypical susceptibility testing and typing of Bacteroides using whole genome sequencing Thomas Vognbjerg Sydenham (Odense, Denmark) Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI) CM SY069 08:30 - 10:30 Hall C Symposium Different perspectives on infectious diseases diagnostics in LMICs ChairsElsie Ilori (Abuja, Nigeria) Michael L. Wilson (Denver, United States) S027108:30Overview of The Lancet Commission on Diagnostics Mikashmi Kohli (Geneva, Switzerland) S027209:00Developing a national essential diagnostics list Kamini Walia (New Delhi, India) S027309:30Current diagnostic capacities, and the impact of COVID-19 in LMICs Adeola Fowotade (Ibadan, Nigeria) S027410:00Review of the contribution of mobile laboratories in the response to outbreaks of VHFs and the COVID-19 pandemic Sayed Shahin (Nairobi, Kenya) Co-organised with: The Lancet Commission on Diagnostics PH SY070 08:30 - 10:30 Hall E Symposium COVID-19: vaccinating the whole world? ChairsNicola Petrosillo (Rome, Italy) Makeda Semret (Montreal, Canada) S027508:30Challenges to reach everyone on Earth Yazdan Yazdanpanah (Paris, France) S027609:00COVID-19 vaccination roll-out: equal access to COVID-19 vaccines and vaccinating hard-to-reach populations Jose Tuells (Alicante, Spain) S027709:30COVID vaccines acceptance and hesitancy Marco Safadi (São Paulo, Brazil) S027810:00Rethinking the ethics of vaccination and use of facemasks: balancing public good with human rights considerations Raquel Duarte (Porto, Portugal) Co-organised with: ESCMID Professional Affairs Subcommittee, ESCMID Study Group on Vaccines (EVASG), ESCMID International Affairs Subcommittee (EIAS), World Association for Infectious Diseases and Immunological Disorders (Waidid) PH SY071 08:30 - 10:30 Hall F Symposium Update on the WHO strategy to eliminate viral hepatitis ChairsArjan Harxhi (Tirana, Albania) Adriana Vince (Zagreb, Croatia) S027908:30The 2021 WHO global progress report Olufunmilayo Lesi (Lagos, Nigeria) S028009:00Monitoring progress towards the elimination targets in EU/EEA countries Erika Duffell (Stockholm, Sweden) S028109:30Viral hepatitis elimination in Turkey Nurcan Baykam (Çorum, Turkey) S028210:00HCV elimination in Egypt Manal Elsayed (Cairo, Egypt) Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH) IC SY072 08:30 - 10:30 Hall J Symposium Supporting evidence in infection prevention and control: 2022 ESCMID guidelines ChairsBiljana Carevic (Belgrade, Serbia) Priscilla Rupali (Velore, India) S028308:30Surgical prophylaxis in patients colonised with multidrug resistant Gram-negatives Evelina Tacconelli (Verona, Italy) S028409:00Surgical prophylaxis in patients colonised with multidrug resistant Gram-positives Jan A.J.W. Kluytmans (Utrecht, Netherlands) S028509:30Screening procedures in healthcare workers and patients during COVID-pandemic Anders Johansson (Umea, Sweden)FINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 202385 Sunday, 24 April 2022 S028610:00Preventing transmission of multidrug resistant Gram-negatives in hospitalised patients Nico Tom Mutters (Bonn, Germany) Co-organised with: EUCIC Steering Committee ID EW07308:30 - 10:30 Hall I Educational Workshop Optimising the use of antibiotics for neonates and children ChairsBojana Beovic (Ljubljana, Slovenia) TBA W028708:30Antibiotic use and stewardship in the PICU Hanna Renk (Tübingen, Germany) W028809:00Antibiotic use and stewardship in the NICU Angelika Berger (Vienna, Austria) W028909:30Surgical prophylaxis in neonates and children Elio Castagnola (Genoa, Italy) Co-organised with: European Society of Paedriatic and Neonatal Intensive Care (ESPNIC) OS074 08:30 - 10:30 Hall G 2-Hour Oral Session SARS-CoV-2 transmission in healthcare environments: detection and prevention ChairsGustavo Daniel Lopardo (Vicente Lopez, Argentina) Andreas Voss (Groningen, Netherlands) O0290Assessment of inhaled SARS-CoV-2 dose per particle size fraction in a standardised COVID-19 patient interaction: a patient proximity sampling study using a highly efficient respiratory particle collector dummy P. Jent* (Bern, Switzerland), E. Zimmermann, O. Al-Khalil, B. Sicre, M. Wider, A. Atkinson, P. Frey, F. Suter, R. Dijkman, J. Marschall O0291Investigation of a nosocomial SARS-CoV-2 cluster in immunocompromised patients by using the association of clinical and viral molecular data J. Andreani* (Grenoble, France), M. Gallouche, A. Caporossi, B. Nemoz, M. Le Maréchal, J. Lupo, H. Jardin, R. Germi, P. Morand, P. Poignard, C. Landelle, S. Larrat O0292SARS-CoV-2 Beta variant outbreak amongst a partially vaccinated long-term care facility population in the Netherlands: phylogenetic analysis and infection control observations N. Van Der Moeren* (Tilburg, Netherlands), V. Weterings, S.D. Pas, J.J. Verweij, W. Van Den Bijllaardt, V.V.F. Zwart, J.A.J.W. Kluytmans, J.L.A.N. Murk, J.J.J.M. Stohr O0293Whole genome sequencing of SARS-CoV-2 to support infection prevention and control practices in the management of acute hospital outbreaks M. Lucey* (Galway, Ireland), E. Mcgrath, S. Whelan, F. Higgins, B. Hanahoe, D. Judith, R. Waldron, U. Ni Riain, M. Cormican, D. Keady O0294A WHO multi-centre case-control study assessing the risk factors for COVID-19 infection in health workers A. Simniceanu* (Geneva, Switzerland), M. Yin, G. Gon, B. Allegranzi, A. Cassini O0295Contextual hospital conditions and the risk of nosocomial SARS-CoV-2 infection: a matched case-control study with density sampling in a large Portuguese hospital F. Almeida* (Porto, Portugal), S. Correia, C. Leal, R. Duro, N. Rocha-Pereira, P. Andrade, S. Pereira, C. Alves, A. Azevedo O0296Estimating the return on investment in selected infection prevention and control interventions in healthcare settings to limit the burden of SARS- CoV-2 A. Cassini* (Geneva, Switzerland), E. Ozcelik, A. Lerouge, B. Allegranzi, M. Cecchini O0297Decentralised sequencing and unified bioinformatics for SARS-CoV-2 outbreak monitoring K. Steinke* (Odense, Denmark), L. Andersen, S.L. Larsen, S.V. Høgh, K.G. Thomsen, M.N. Skov, T.V. Sydenham O0298Reconstructing transmission chains of SARS- CoV-2 amid multiple outbreaks in a geriatric acute-care hospital M. Abbas* (Geneva, Switzerland), A. Cori, S. Cordey, F. Laubscher, T. Robalo Nunes, J. Salamun, P. Huber, D. Zekry, V. Prendki, A. Iten, L. Vieux, V. Sauvan, C. Graf, S. Harbarth O0299Digital droplet PCR to track SARS-CoV-2outbreak in a hospitaltransitionalcare unit L. Oberding* (Calgary, Canada), K. Linton, J. Kim, D. Pillai OS075 08:30 - 10:30 Hall H 2-Hour Oral Session Clinical PK/PD studies and TDM to improve dosing of anti- infectives ChairsBirgit Koch (Rotterdam, Netherlands) Sebastian Wicha (Hamburg, Germany) O0300Population toxicodynamics (TD) of intravenous polymyxin B (PB) in critically ill patients enrolled in an ongoing multi-centre prospective cohort study: prediction of incidence of acute kidney injury (AKI) G. Rao* (Chapel Hill, United States), P. Hanafin, A. Kwa, A. Zavascki, A. Sandri, M. Scheetz, C. Kubin, J. Shah, B. Cherng, M. Yin, J. Wang, L. Wang, A. Purcell, R. Nation, K. Kaye, J. Li O0301Development of modernisedAcinetobacter baumannii susceptibility guidance for recommended antimicrobial agents using pharmacometric approaches A. Lepak* (Madison, United States), B. Vanscoy, H. Sader, M. Trang, J. Hammel, S. Bhavnani, P. Ambrose, D. AndesSCIENTIFIC PROGRAMME86 Sunday, 24 April 2022 O0302Model-based TDM of vancomycin: a retrospective comparison with routine TDM-based dosing M. Gijsen* (Leuven, Belgium), H. Gastmans, E. Dreesen, N. Dia, S. Desmet, K. Lagrou, W. Peetermans, Y. Debaveye, I. Spriet O0303Population pharmacokinetics and dosing simulations of cefoxitin administered by continuous IV in critically ill patients P. Chabert* (Lyon, France), J. Provoost, S. Cohen, T. Ferry, J.C. Richard, S. Goutelle O0304Pharmacokinetics and PK/PD of temocillin in non-ICU urinary tract infection patients with various stages of renal insufficiency G. Wijnant* (Brussels, Belgium), P. Ngougni Pokem, M. Coessens, E. Cottone, L. Goeman, S. Vervaeke, F. Van Bambeke O0305Pharmacokinetics and safety of colistin in older adults with extensively drug-resistant Gram- negative bacterial infections S. Luque* (Barcelona, Spain), L. Sorli, I. Arnau, R. Güerri, N. Campillo, J. Gomez-Junyent, I. Pelegrin, S. Gómez-Zorrilla, I. Lopez, M. Arenas, M. Montero, S. Grau, J.P. Horcajada O0306Population pharmacokinetics and probability of target attainment analyses of ceftolozane/ tazobactam in paediatric participants J. Chittenden* (Kenilworth, United States), N. Noormohamed, S. Basu, W. Gao, M.G. Johnson, C.J. Bruno, H.P. Feng O0307Therapeutic drug monitoring of orally administered letermovir prophylaxis in allogeneic haematopoietic cell transplant recipients L. Royston* (Geneva, Switzerland), S. Masouridi- Levrat, Y. Chalandon, C. Pressacco-Brossier, Y. Abi Aad, D. Tonoli, A. Karmime, M. Jayo, V. Gotta, M. Pfister, C. Van Delden, P. Lescuyer, D. Neofytos O0308Plasma pharmacokinetics and intrapulmonary penetration of tebipenem in healthy subjects K. Rodvold* (Chicago, United States), M. Gotfried, V. Gupta, A. Ek, Y. Lei, P. Srivastava, A. Talley, J. Bruss O0309Amoxicillin crystalluria in patients receiving high doses of intravenous amoxicillin: incidence, associated factors and impact on renal function, the CRISTAMOX study M. Hentzien* (Reims, France), S. Demotier, A. Limelette, A. Charmillon, E. Baux, X. Parent, S. Mestrallet, S. Pavel, A. Servettaz, M. Dramé, A. Muggeo, A. Wynckel, C. Gozalo, M. Abou Taam, A. Fillion, R. Jaussaud, T. Trenque, L. Piroth, F. Bani-Sadr OS076 08:30 - 10:30 Hall K 2-Hour Oral Session Endocarditis, mice and men ChairsXavier Duval (Paris, France) José M. Miro (Barcelona, Spain) O0310Culture negative endocarditis and the value of a definite diagnosis: results from a tertiary care centre of northern Italy T.C. Pieri* (Pavia, Italy), E. Seminari, P. Cambieri, S. Roda, M. Colaneri, I. Gallazzi, E. Asperges, E. Bono, L.N. Marvulli, R. Lissandrin, R. Bruno O0311Bone marrow and spleen hypermetabolism as indirect signs of infection in an experimental endocarditis animal model C. García De La Mària* (Barcelona, Spain), A. Perissinotti, M. Collantes, J. Llopis, M. Ecay, M.J. García-Velloso, J. García González, M.A. Cañas, M. Hernández-Meneses, A. Moreno, I. Peñuelas, D. Fuster, J.M. Miró O0312Efficacy of the activity of daptomycin with ceftaroline against isolated Staphylococcus epidermidis causing infectious endocarditis C. García De La Mària* (Barcelona, Spain), M. Cañas, M. Hernández Meneses, J. García González, A. Dahl, C. Falces, E. Quintana, J. Llopis, J. Ambrosioni, F. Marco, B. Vidal, A. Perissinotti, J.M. Tolosana, E. Sandoval, A. Moreno, J.M. Miró O0313Epidemiology, clinical characteristics and outcome of 187 patients with infective endocarditis from 2009 to 2021 at two university hospitals, in Rio de Janeiro, Brazil P. Damasco* (Rio de Janeiro, Brazil), L. Sousa, V. Solórzano, N. Rodrigues, A. Siebra, H. Coutinho, R. Leão, E. Lemos, C. Fortes O0314Outpatient parenteral antimicrobial therapy (OPAT) for infective endocarditis: convenient and feasible L.E. Lopez-Cortés* (Seville, Spain), R. Luque- Márquez, L. Hidalgo-Herrera, M.D. Navarro-Amuedo, J. Praena-Segovia, M.V. Gil-Navarro, A. Alarcón- Gonzalez O0315Influence of the antithrombotic therapy in the prognosis of infective endocarditis J.T. Solera* (Toronto, Canada), L. Domínguez Pérez, P. Muñoz, M. Martínez-Sellés, A. De Alarcón, C. Rico, L. García, M.Á. Goenaga, J. Goikoetxea, R. Rodríguez, J. De La Torre, D. Escribano, L. Boix, L. Castelo, F. López Medrano O0316Infective endocarditis and cardiovascular outcomes after transcatheter and surgical aortic valve replacement: a population-based cohort study M. Purtak* (Aarau, Switzerland), A. Kutz*, A. Conen* O0317Risk factors for Gram-negative infection of cardiovascular implantable electronic devices: retrospective multi-centre study, CarDINe study R. Pascale* (Bologna, Italy), A.T. Aslan, A. Maccaro, G. Massaro, A. Toschi, D. Fabbricatore, T. De Potter, M. Ripa, P. Scarpellini, A. Karruli, E. Durante-Mangoni, K. Akinosoglou, G. Leventopulos, M. Papadimitriou-Olivgeris, G. Domenichini, E.E. Özcan, O.E. Turan, M. Yilmaz, M. Sahin, M.C. Isik, B. Kayaaslan, Y.A. Bilir, S. Iacopino, F. Placentino, M. Akova, I. Diemberger, P. Viale, M. GiannellaFINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 202387 Sunday, 24 April 2022 O0318Systemic embolism in infective endocarditis J. Constán* (Granada, Spain), C. López-Robles, M.C. García, C. Fernández-Roldán, R. Javier O0319Risk of infective endocarditis associated with transcatheter aortic valve implantation versus surgical aortic valve replacement: a propensity score-based analysis on a prospective cohort J. Calderon Parra* (Majadahonda, Spain), J.E. De Villarreal-Soto, J.F. Oteo-Domínguez, C. Arellano-Serrano, M. Mateos-Seirul, D. Martínez- López, L. Dorado, E.C. Ríos-Rosados, A. Ramos- Martínez, A. Forteza-Gil OS07708:30 - 09:30 Hall D 1-Hour Case Session Challenges associated with Capnocytophaga infections ChairEls Broens (Utrecht, Netherlands) O0320Same pathogen, different outcome in immunocompetent patients: Capnocytophaga canimorsus; report of two cases A. Perez-Ugarte* (Barcelona, Spain), S. Levy- Blitchtein, P. Salmeron, M. Belsol, P.S. Corona, D. Rodríguez-Pardo, N. Fernández-Hidalgo, C. Amat, M. Lung O0321Capnocytophaga canimorsusmeningitis: a nationwide population-based case series L. Duerlund* (Aalborg, Denmark), H. Nielsen, J. Bodilsen O0322Capnocytophaga canimorsus: not always the dog is the man´s best friend D. Fernández Vecilla* (Bilbao, Spain), I. Angulo López, F.E. Calvo Muro, C. Aspichueta Vivanco, F. Renzi, M.E. Pereda Martínez, J. Roselló Soria, J.L. Díaz De Tuesta Del Arco O0323Capnocytophaga canimorsus multifocal mycotic aneurysms in an immunocompetent adult C. Sun* (Adelaide, Australia), A. Fitzpatrick, E. Tucker O0324Lethal Waterhouse-Friderichsen syndrome caused by Capnocytophaga canimorsus in an asplenic patient F. Schuler* (Münster, Germany), J.S. Padberg, C. Hullermann, P. Kümpers, J. Lepper, M. Schulte, A. Uekötter, F. Schaumburg, C.B. Kahl VW078 08:30 - 09:30 Arena 2 Virtual Walk Through Multiple drug-resistant bacteria and COVID-19: a double whammy ModeratorGian Maria Rossolini (Florence, Italy) ReviewerSarah Tschudin Sutter (Basel, Switzerland) VW079 09:30 - 10:30 Arena 1 Virtual Walk Through Staphylococcus aureus, a long way to the top ModeratorBarbara C. Kahl (Münster, Germany) ReviewerSerap Simsek Yavuz (Erenkoy, Istanbul, Turkey) PH KN08011:00 - 12:00Hall A Keynote lecture Dealing with the complexity of pandemics: the future is now Chairs Marion Koopmans (Rotterdam, Netherlands) Jacob Moran-Gilad (Be'er Sheva, Israel) K032511:00 Chikwe Ihekweazu (Berlin, Germany) Dr Chikwe Ihekweazu is the Assistant Director General at WHO for Surveillance and Health Emergency Intelligence and leads the WHO Hub for Pandemic and Epidemic Intelligence, based in Berlin, Germany. Previously, Dr Ihekweazu was the firstDirectorGeneraloftheNigeriaCentreforDiseaseControl (NCDC), which he led July 2016 - October 2021, building it from a small unit to a leading public health agency in Africa. He acted as Interim Director of the West Africa Regional Centre for Surveillance and Disease Control through 2017. He trained as an infectious disease epidemiologist and has over 25 years’ experience working in senior public health and leadership positions in national public health institutes including NCDC, South African National Institute for Communicable Diseases, the UK's Health Protection Agency, and Germany’s Robert Koch Institute. Dr Ihekweazu has led several short-term engagements for WHO, mainly building surveillance systems and responding to major infectious disease outbreaks. He waspartofthefirstWHOCOVID-19internationalmissionto China. Dr Ihekweazu is a graduate of the College of Medicine, University of Nigeria and has a Master’s in Public Health from the Heinrich-Heine University, Dusseldorf, Germany. In 2003, he was awarded a Fellowship for the European Programme for Intervention Epidemiology Training and subsequentlycompletedhisPublicHealthspecialisation in the UK. He has over one hundred publications in medical peer review journals, mostly focused on the epidemiology of infectious diseases. Dr Ihekweazu is on the board of several NGOs; he was also a TED Fellow and co-founded and delivered the TEDxEuston event from 2009 to 2019. Fireplace Session24 April, 12:30 - 13:30SCIENTIFIC PROGRAMME88 Sunday, 24 April 2022 ID SY081 11:00 - 12:00 Hall C Symposium Hepatitis E: an update ChairsGülsen Özkaya Sahin (Lund, Sweden) Zeinab Said (Cairo, Egypt) S032611:00Transfusion-associated fulminant HEV infection Heli Harvala (London, United Kingdom) S032711:30Prospects for an HEV vaccine Susanne Gjeruldsen Dudman (Oslo, Norway) Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH) ID SY082 11:00 - 12:00 Hall E Symposium Year in Infectious Diseases ChairsGraeme Ayton Meintjes (Cape Town, South Africa) Joanne M Langley (Halifax, Canada) S032811:00Synne Jenum (Oslo, Norway) S032911:30Elena Carrara (Verona, Italy) CM SY083 11:00 - 12:00 Hall F Symposium Fighting biofilm with non-traditional antibacterials ChairsRan Nir-Paz (Jerusalem, Israel) Zuzanna Drulis-Kawa (Wroclaw, Poland) S033011:00Antisense therapy against biofilms Nuno Azevedo (Porto, Portugal) S033111:30Phage-inspired leads for antibiotics Rob Lavigne (Leuven, Belgium) Co-organised with: ESCMID Study Group for Non- traditional Antibacterial Therapy (ESGNTA), ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS) ID SY084 11:00 - 12:00 Hall I Symposium Combination therapies: from models to patients ChairsAlexia Chauzy (Poitiers, France) Yunsong Yu (Hangzhou, China) S033211:00Favourable combination therapies evidence from pre-clinical studies Thomas Tängdén (Uppsala, Sweden) S033311:30Combination therapies in clinical trials: what is the evidence? Dafna Yahav (Petah-Tikva, Israel) CM SY085 11:00 - 12:00 Hall N Symposium Updates on antimicrobial susceptibility testing of mycobacteria ChairsFlorian Maurer (Borstel, Germany) Thomas Schön (Kalmar, Sweden) S033411:00Updates and open questions on the recently revised WHO critical concentrations for antimicrobial susceptibility testing of Mycobacterium tuberculosis complex Claudio Köser (Cambridge, United Kingdom) S033511:30The EUCAST approach for drug susceptibility testing of mycobacteria: past, present, future Emmanuelle Cambau (Paris, France) Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), EUCAST Subcommittee on Antimycobacterial Susceptibility Testing (EUCAST-AMST) OS086 11:00 - 12:00 Hall B 1-Hour Oral Session Rapid detection of emerging SARS-CoV-2 variants ChairsSimona Ruta (Bucharest, Romania) Anja Šterbenc (Ljubljana, Slovenia) O0336Comparative analysis of five multiplex real-time RT-qPCR assays in the screening of SARS-CoV-2 variants I. Giberti* (Genoa, Italy), V. De Pace, B. Bruzzone, A. Orsi, V. Ricucci, A. Domnich, G. Guarona, N. Randazzo, F. Stefanelli, E. Battolla, P.A. Dusi, F. Lillo, G. Icardi O0337Early detection of SARS-CoV-2 variants through the application of SNP based genotyping in anational surveillance programme S. Choudhry* (London, United Kingdom), M. Edmunds, W. Sopwith, H. Vansteenhouse, M. Wigglesworth, J.A. O’hare, J. Turner, M.A. Amphlett, M.L. Smith, J. Cogdale, J. Ellis, A. Lackenby, K. Mcclelland, T. Rowland, K. Rajput, P. Jacobs, J. Feenstra, A.F. Dominiczak, M. Zambon O0338Clinical evaluation of commercial SARS-CoV-2 variant assays A. De Salazar* (Granada, Spain), A. Fuentes-López, L. Viñuela, N. Chueca, F. García O0339Identification of SARS-CoV-2 lineage and mutations with a rapid SARS-CoV-2 genotyping assay C. Lee* (Singapore, Singapore), I. Ng, B. Han, F. Kadir, A. Aizin, H. Suhardi, M. Aye, A.W. Kyaw, P. Ariyaratne, W.K. Lye, R. Luo O0340A metagenomics workflow for SARS-CoV-2 identification, co-pathogen detection, and overall metagenome diversity in clinical isolates D. Castañeda-Mogollón* (Calgary, Canada), C. Kamaliddin, L. Oberding, Y. Liu, M.A.N. Mohon, F. Rehan, F. Khan, D. PillaiFINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 202389 Sunday, 24 April 2022 OS087 11:00 - 12:00 Hall G 1-Hour Oral Session UTI: from mild to complicated, from diagnosis to treatment ChairsMarco Falcone (Pisa, Italy) Cees Van Nieuwkoop (The Hague, Netherlands) O0341Use of urinary dip sticks in hospital care: a population-based cohort study W. Rannva* (Aalborg, Denmark), R. Winther, L.H. Kristensen, H. Nielsen, J. Bodilsen O0342Effectiveness and safety of intravenous fosfomycin in complicated urinary tract infection in real-life conditions: preliminary results from a matched-cohort study (FOSFO-MIC) E. Moreno-Mellado* (Seville, Spain), E. León Jiménez, C. Garrigós, S. De La Rosa-Riestra, J. Liró Armenteros, J.L. Rodríguez-Ochoa, E.L.I.S.A. Asensio Gallego, M. Akova, C.D. Zeynep, A. Tarik Aslan, D. Vinuesa, E. Moral Escudero, N. Chacón Mora, Á. Cano, Á. Pascual Hernández, J. Rodríguez- Baño, F. Docobo Pérez, B. Gutiérrez-Gutiérrez O0343Effectiveness at day 5 of antimicrobial treatment for uncomplicated febrile urinary tract infection in children between 3 months to 18 years old, pilot study PEDIU5 A. Zeggay* (Besançon, France), A. Ladaurade, A. Potron, A.L. Parmentier, G. Thiriez, R. Anxionnat O0344Bacterial genome-wide association study identifies papGII to be associated with invasive uropathogenic E. coliinfections A. Cuénod* (Basel, Switzerland), J. Agnetti, H. Seth-Smith, T. Roloff, S. Tschudin-Sutter, S. Bassetti, N.R. Thomson, A. Egli O0345The comparative efficacy of various oral therapeutics to treat mild urinary tract infections, which are managed in the community, caused by extended-spectrum beta-lactamase producing Enterobacterales (ESBL) D. Marchaim* (Be’er Ya’akov, Israel), E. Levy, S. Zilberman-Itskovich, I. Levi, M. Iflah, K. Amity, R. Finkenberg OS088 11:00 - 12:00 Hall H 1-Hour Oral Session Resistance markers in sexually transmitted bacteria ChairsBenjamin Bluemel (Solna, Sweden) Angelika Stary (Vienna, Austria) O0346Emergence of extended-spectrum beta- lactamases producing Shigella sonnei among men who have sex with men in Barcelona A. Moreno-Mingorance* (Barcelona, Spain), V. Rodriguez-Garrido, L. Goterris, Y. Hoyos-Mallecot, M.J. Barberà, M. Alberny, E. Sulleiro, A. Mir-Cros, J. Roca-Grande, T. Cornejo-Sánchez, B. Viñado, T. Pumarola, M.N. Larrosa, J.J. González-López O0347N. gonorrhoeae azithromycin resistance: the push and pull of evolutionary forces P. Campbell* (Oslo, Norway), L.M. Brendefur Corwin, J.V. Bjørnholt, A.O. Olsen, T.M. Leegaard O0348Fluoroquinolone resistance-associated mutations in Mycoplasma genitalium among men with urethritis and other clients of two Sexual Health Centres in the Netherlands J. Braam* (Amsterdam, Netherlands), H.C.A. Zondag, S.M. Bruisten, H.J.C. De Vries, C.E. Vergunst, M.F. Schim Van Der Loeff, A.P. Van Dam O0349The Neisseria gonorrhoeae accessory genome and its association with the core genome and antimicrobial resistance J. De Korne-Elenbaas* (Amsterdam, Netherlands), S.M. Bruisten, A.P. Van Dam, M.C.J. Maiden, O.B. Harrison O0350Distinct Mycoplasma genitalium transmission networks among women and PrEP users in France J. Guiraud* (Bordeaux, France), M. Helary, C. Le Roy, S. Pereyre, C. Bébéar OS089 11:00 - 12:00 Hall Q 1-Hour Oral Session Pathophysiology and prognosis in COVID-19 infection ChairsChrysanthi Skevaki (Marburg, Germany) Snjezana Zidovec Lepej (Zagreb, Croatia) O0351Biological and clinical significance of natural circulating and airway neutralising antibodies to IFN-I in COVID-19 patients F. Frasca* (Rome, Italy), M. Scordio, L. Sorrentino, M. Fracella, G. Oliveto, A. Viscido, C. Bitossi, A. D’auria, G. Bugani, L. Santinelli, A. Pierangeli, L. Celani, G. Ceccarelli, C.M. Mastroianni, G. D’ettorre, G. Antonelli, C. Scagnolari O0352High levels of IL-6 and SARS-CoV-2 viral load and low expression of CCL5 in the upper respiratory tract are associated with severe COVID-19 F. Pérez-García* (Majadahonda, Spain), M. Martín- Vicente, R.L. Rojas-García, L. Castilla-García, M.J. Muñoz-Gómez, I. Hervás Fernández, V. González Ventosa, E.J. Vidal-Alcántara, J. Cuadros-González, M.Á. Jiménez-Sousa, A. Fernández-Rodríguez, J.F. Bermejo-Martín, S. Resino, I. Martínez O0353Evaluation of neurofilament light chain in cerebrospinal fluid and plasma samples of COVID-19 patients with neurological symptoms M.A. Zingaropoli* (Rome, Italy), M. Iannetta, L. Piermatteo, P. Pasculli, L. Mazzuti, R. Scutari, L. Onori, L. Campogiani, G. Ferraguti, G. Antonelli, M. Andreoni, C.M. Mastroianni, O. Turriziani, F. Ceccherini-Silberstein, L. Sarmati, M.R. Ciardi O0354COVID-19 alters oral microbiome in closed community on a cruise ship K. Ota* (Nagasaki, Japan), D. Sasaki, F. Mitsumoto-Kaseida, K. Sakamoto, K. Kosai, H. Hasegawa, K. Yamamoto, K. Izumikawa, H. Mukae, K. YanagiharaNext >